A China-based pharmaceutical company has a headcount of over 7,000 and has more than 40 branches and subsidiaries around the world. The company’s main businesses are in API and generics, although they are rapidly expanding into innovation drug areas such as small molecule drugs, biologics, and cell therapies. The firm has a US subsidiary, an integrated business with capabilities in R&D, manufacturing, and Sales and Marketing. The firm sells generic drugs to major pharmacy chains like CVS and Walgreens, department stores like Walmart and Costco, major grocery stores, etc. 

The firm also has an investment subsidiary that conducts equity investments and BD activities (in-licensing, supplier/distributor agreements, etc.) for both the China and US markets. 
 
The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilar. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA). 

While the firm welcomes proposals on various equity investment and BD opportunities, the firm is currently also interested specifically in the following: 

-Late clinical stage assets that can be in-licensed and introduced to the China market; 

-Technologies that can be used to improve API production; 

-Injectable drugs; 

The firm is also interested in distribution rights in China (for both innovation and generic drugs) and in the US (mainly for generic drugs). 
 
The firm has no specific company or management team requirements.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in Western Europe is entirely specialized in and focused on investing in early-stage oncology drug development companies. Through its oncology-focused funds, the firm has invested in 13 early stage companies, of which 6 were founded by the firm. The firm’s main focus is on European companies, although they will consider US opportunities. 
 
The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies. 
 
The firm can support management teams by being operationally involved on an interim basis in companies located close to the firm, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment arm of a leading health system has invested in over 30 companies (with 10 successful exits to date) as well as a few healthcare funds. The firm currently manages over $250M AUM. The firm currently invests from its latest fund that closed in 2022, and generally invests in Series A and B rounds. The firm focuses on investing in solutions that can improve patient outcomes, enhance patient experience, and reduce the cost of healthcare. The firm invests primarily in USA-based companies. 
 
The firm invests in therapeutics, medical devices, diagnostics, healthcare IT and technology-enabled delivery solutions. In terms of stage of development, the firm is looking for those that have already received seed funding and companies are expected to demonstrate strong clinical data/validation. In terms of medical devices, the companies should have a working prototype in place. The firm is capable of investing in all classes of medical devices including those requiring 510(k) and PMA regulatory approval. The firm is open to all types of technologies and indications but prefers those that address an area of large unmet need, including chronic disease management, mental & behavioral health, cardiovascular disease, precision medicine, etc. The firm is also interested in technologies that involve advanced applications of AI. 
 
The firm has no specific company or management team requirements. While the firm has led investment rounds and would seek board representation in those instances, the firm generally acts as a syndicate investor alongside likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 2020 and based in the US, a life science venture capital arm of a large corporation is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities. 
 
The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm is open to any indication area including oncology, CNS diseases and rare diseases. 
 
The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.